The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality
Open accessAbstract
Importance: Black men are more likely to die of prostate cancer than white men. In men with similar stages of disease, the contribution of biological vs nonbiological differences to this observed disparity is unclear. Objective: To quantify the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer. Design, Setting, and Participants: This multiple-cohort study included updated individual patient-level data of men with clinical T1-4N0-1M0 prostate cancer from the following 3 cohorts: Surveillance, Epidemiology, and End Results (SEER [n = 296 273]); 5 equal-access regional medical centers within the Veterans Affairs health system (VA [n = 3972]); and 4 pooled National Cancer Institute-sponsored Radiation Therapy Oncology Group phase 3 randomized clinical trials (RCTs [n = 5854]). Data were collected in the 3 cohorts from January 1, 1992, through December 31, 2013, and analyzed from April 27, 2017, through April 13, 2019. Exposures: In the VA and RCT cohorts, all patients received surgery and radiotherapy, respectively, with curative intent. In SEER, radical treatment, hormone therapy, or conservative management were received. Main Outcomes and Measures: Prostate cancer-specific mortality (PCSM). Secondary measures included other-cause mortality (OCM). To adjust for demographic-, cancer-, and treatment-related baseline differences, inverse probability weighting (IPW) was performed. Results: Among the 306 100 participants included in the analysis (mean [SD] age, 64.9 [8.9] years), black men constituted 52 840 patients (17.8%) in the SEER cohort, 1513 (38.1%) in the VA cohort, and 1129 (19.3%) in the RCT cohort. Black race was associated with an increased age-adjusted PCSM hazard (subdistribution hazard ratio [sHR], 1.30; 95% CI, 1.23-1.37; P < .001) within the SEER cohort. After IPW adjustment, black race was associated with a 0.5% (95% CI, 0.2%-0.9%) increase in PCSM at 10 years after diagnosis (sHR, 1.09; 95% CI, 1.04-1.15; P < .001), with no significant difference for high-risk men (sHR, 1.04; 95% CI, 0.97-1.12; P = .29). No significant differences in PCSM were found in the VA IPW cohort (sHR, 0.85; 95% CI, 0.56-1.30; P = .46), and black men had a significantly lower hazard in the RCT IPW cohort (sHR, 0.81; 95% CI, 0.66-0.99; P = .04). Black men had a significantly increased hazard of OCM in the SEER (sHR, 1.30; 95% CI, 1.27-1.34; P < .001) and RCT (sHR, 1.17; 95% CI, 1.06-1.29; P = .002) IPW cohorts. Conclusions and Relevance: In this study, after adjustment for nonbiological differences, notably access to care and standardized treatment, black race did not appear to be associated with inferior stage-for-stage PCSM. A large disparity remained in OCM for black men with nonmetastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Cancer Disparities by Race/Ethnicity and Socioeconomic Status
Ward, E., Jemal, A., Cokkinides, V., Singh, G. K., Cardinez, C., Ghafoor, A., & Thun, M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.78 · Cited by 1,801
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Self-citation(2006) · Cancer · doi:10.1002/(issn)1097-0142 · Cited by 1,470
State of disparities in cardiovascular health in the United States.
Mensah, G. A., Mokdad, A. H., Ford, E. S., Greenlund, K. J., & Croft, J. B. (2005) · Circulation · doi:10.1161/01.cir.0000158136.76824.04 · Cited by 1,213 · cited 1×
“In sensitivity analysis to understand the association of baselinecharacteristicdifferenceswithoutcomes,stepwiseIPWmodels were developed as follows: (1) age-adjusted IPW, which only weightsimbalancesinage;(2)age-andstage-adjustedIPW,which weights imbalances in age and cancer-specific prognostic variables; and (3) fully…”
Method20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups
Yost, K., Perkins, C., Cohen, R., Morris, C., & Wright, W. (2001) · Cancer Causes & Control · doi:10.1023/a:1011240019516 · Cited by 965
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citationDeSantis, C. E., Siegel, R. L., Sauer, A. G., Miller, K. D., Fedewa, S. A., Alcaraz, K. I., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21340 · Cited by 790
Survival of Blacks and Whites After a Cancer Diagnosis
Bach, P. B. (2002) · JAMA · doi:10.1001/jama.287.16.2106 · Cited by 513
Latouche, A., Allignol, A., Beyersmann, J., Labopin, M., & Fine, J. P. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.09.017 · Cited by 503
Brancati, F. L., Kao, W. H. L., Folsom, A. R., Watson, R. L., & Szklo, M. (2000) · JAMA · doi:10.1001/jama.283.17.2253 · Cited by 501
Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study
Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C., & Potosky, A. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.5.388 · Cited by 441
The Use and Interpretation of Competing Risks Regression Models
Dignam, J. J., Zhang, Q., & Kocherginsky, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2097 · Cited by 357
Self-citationEstimating Treatment Effects Using Observational Data
D’Agostino, R. B. (2007) · JAMA · doi:10.1001/jama.297.3.314 · Cited by 350
Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer
Albertsen, P. C., Moore, D. F., Shih, W., Lin, Y., Li, H., & Lu-Yao, G. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2330 · Cited by 312
Feuer, E. J., Merrill, R. M., & Hankey, B. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.12.1025 · Cited by 251
Limits of observational data in determining outcomes from cancer therapy
Giordano, S. H., Kuo, Y., Duan, Z., Hortobagyi, G. N., Freeman, J., & Goodwin, J. S. (2008) · Cancer · doi:10.1002/cncr.23452 · Cited by 206
Jagsi, R., Abrahamse, P., Hawley, S. T., Graff, J. J., Hamilton, A. S., & Katz, S. J. (2012) · Cancer · doi:10.1002/cncr.26295 · Cited by 191
Austin, P. C., & Schuster, T. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280213519716 · Cited by 191
Comparison of Population-Based Observational Studies With Randomized Trials in Oncology
Soni, P. D., Hartman, H. E., Dess, R. T., Abugharib, A., Allen, S. G., Feng, F. Y., Zietman, A. L., Jagsi, R., Schipper, M. J., & Spratt, D. E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01074 · Cited by 171
Self-citationLimitations and Biases of the Surveillance, Epidemiology, and End Results Database
Park, H. S.-M., Lloyd, S. A. J., Decker, R. H., Wilson, L. D., & Yu, J. B. (2012) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2012.03.011 · Cited by 134
Halabi, S., Dutta, S., Tangen, C. M., Rosenthal, M. A., Petrylak, D. P., Thompson, I. M., Chi, K. N., Araujo, J. C., Logothetis, C. J., Quinn, D. I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01279 · Cited by 132
Self-citationMahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M., Choueiri, T. K., Hu, J. C., Sweeney, C. J., Beard, C. J., et al. (2014) · Urology · doi:10.1016/j.urology.2014.05.009 · Cited by 96
Self-citationRace, Ancestry, and Medical Research
Fontanarosa, P., & Bauchner, H. (2018) · JAMA · doi:10.1001/jama.2018.14438 · Cited by 70
Roach, M., Lu, J., Pilepich, M. V., Asbell, S. O., Mohiuddin, M., & Grignon, D. J. (2003) · The Journal of Urology · doi:10.1016/s0022-5347(05)64078-5 · Cited by 52
Self-citationSpratt, D. E., Chen, Y., Mahal, B. A. V., Osborne, J. R., Zhao, S. G., Morgan, T. M., Palapattu, G. S., Feng, F. Y.-C., & Nguyen, P. L. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.03.010 · Cited by 34
Self-citationCan Observational Data Replace Randomized Trials?
McGale, P., Cutter, D., Darby, S. C., Henson, K. E., Jagsi, R., & Taylor, C. W. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8879 · Cited by 32
Cited by
2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Bergengren, O., Pekala, K. R., Matsoukas, K., Fainberg, J., Mungovan, S. F., Bratt, O., Bray, F., Brawley, O., Luckenbaugh, A. N., Mucci, L., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.04.021 · Cited by 848
Self-citationThe Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationEpidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Self-citationCancer statistics for African American/Black People 2022
Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21718 · Cited by 574
Metadata
- Authors
- Dess, R. T., Hartman, H. E., Mahal, B. A., Soni, P. D., Jackson, W. C., Cooperberg, M. R., Amling, C. L., Aronson, W. J., Kane, C. J., Terris, M. K., Zumsteg, Z. S., Butler, S., Osborne, J. R., Morgan, T. M., Mehra, R., Salami, S. S., Kishan, A. U., Wang, C., Schaeffer, E. M., Roach, M., Pisansky, T. M., Shipley, W. U., Freedland, S. J., Sandler, H. M., Halabi, S., Feng, F. Y., Dignam, J. J., Nguyen, P. L., Schipper, M. J., & Spratt, D. E.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-07-01
- Volume
- 5
- Issue
- 7
- Pages
- 975
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2944891078
- Cited by
- 414
- References
- 30
- FWCI
- 36.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.